军事知识服务平台
中剂量环磷酰胺联合甲泼尼龙治疗重症肌无力危象的随机对照临床研究
Randomized controlled clinical trial of middle-dose cyclophosphamide plus methylprednisolone for myasthenia gravis patients in crisis
摘要 目的 评价中剂量环磷酰胺(CTX)联合甲泼尼龙治疗重症肌无力(MG)危象的有效性与安全性.方法 采用前瞻、开放、平行和随机对照的研究方法,选择1999年1月至2010年10月在中山大学附属第一医院神经科就诊的156例重症肌无力危象患者作为研究对象,其中CTX组与对照组各78例.CTX组予甲泼尼龙500 mg/d连用3d,后改为250 mg/d,每隔3d剂量减半,直到62.5 mg/d改泼尼松30 mg/d口服维持至试验结束.同时加用CTX 0.4 g静脉推注,连用3d后改为0.4g,隔3 d一次.对照组单独应用甲泼尼龙.根据MG的临床绝对和相对评分法评定疗效.结果 (1) CTX组中54例(69.2%)患者3d内呼吸困难消失,而对照组中36例(46.2%)患者在8~14 d内呼吸困难消失,两组比较差异有统计学意义(P =0.000).(2) CTX组中超过一半的患者在10~14 d内肢体无力(44例,56%)与吞咽功能(47例,60.3%)得到明显的改善,而同样情况的对照组患者28 d后症状改善.两组比较差异有统计学意义(P =0.000).(3) CTX组中,54例(69.2%) MG患者应用CTX总量达到1.2g时呼吸困难消失,而超过一半的患者在CTX总量达到2.8g时才出现吞咽困难(47例,60.3%)与肢体无力(44例,56.4%)的恢复,3组症状改善时需要的CTX总量的差异比较有统计学意义(P =0.000).(4) CTX组在治疗期间并发肺部感染17例(21.8%),对照组并发肺部感染53例(67.9%),两组肺部感染的发生率比较差异有统计学意义(P =0.000).(5) CTX组患者所出现的不良反应短暂且轻微.结论 (1)中剂量CTX联合甲泼尼龙治疗重症肌无力危象是有效且安全的.(2)与甲泼尼龙联用,当CTX总量达到1.6g时,90%的重症肌无力危象患者能成功脱机.
Abstract:
Objective To evaluate the efficacy and safety of middle-dose cyclophosphamide plus methylprednisolone for myasthenia gravis (MG) patients in crisis.Methods For this prospective,open,parallel,randomized controlled trial,we recruited a total of 156 MG patients in crisis from January 1999 to October 2011 at Department of Neurology,First Affiliated Hospital,Sun Yat-sen University.They were divided into two groups of cyclophosphamide and control ( n =78 each).In the cyclophosphamide group,each received methylprednisolone 500 mg/d for 3 days,then tapered to 250 mg/d and tapered half every 3 days until 62.5 mg/d.Afterward an oral dose of prednisone was prescribed at 30 mg/d until the end of the trial.At the same time,an intravenous injection of cyclophosphamide was offered at 0.4 g/d for 3 days and then 0.4 g/d every 3 days.In the control group,each received methylprednisolone alone.And the efficacies were assessed by absolute and relative MG scores.Results ( 1 ) There were 54 ( 69.2% ) patients offventilation in 3 days in the cyclophosphamide group versus 36 (46.2% ) patients in 8-14 days in the control group.Notable statistical significance existed between two groups (P =0.000).(2) More than half of the patients in cyclophosphamide group with extremity weakness ( n =44,56% ) and dysphagia ( n =47,60.3% ) significantly improved in 10-14 days versus 28 days in the control group.Notable statistical significance existed between two groups ( P =0.000 ).( 3 ) In the cyclophosphamide group,dyspnea disappeared in 54 (69.2% ) patients when the dose reached 1.2 g.The recovery of dysphagia ( n =47,60.3% ) and extremity weakness (n =44,56.4% ) occurred in more than half of the patients when the dose reached 2.8 g.Notable statistical significance existed among three groups ( P =0.000 ).( 4 ) During the treatment period,there were 17 cases (21.8%) with pulmonary infection in the cyclophosphamide group versus 53 cases (67.9%) in the control group.Notable statistical significance existed between two groups (P=0.000).(5) Brief and minor side effects appeared in the patients of the cyclophosphamide group.Conclusion ( 1 ) The combined treatment of middle-dose cyclophosphamide and methylrednisolone for MG patients in crisis is both effective and safe.(2) When combined with methylrednisolone,90% of patients with MG crisis are successfully off-ventilation when the dose of cyclophosphamide reaches 1.6 g.
Author: FENG Hui-yu LIU Wei-bin QIU Li HUANG Xin LUO Chuan-ming LI Yan WANG Hai-yan
作者单位: 中山大学附属第一医院神经内科,广州,510080
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2012, 92(35)
分类号: R978.1
机标分类号: R96 R73
在线出版日期: 2012年12月28日
基金项目: (2011 81071002):国家自然科学基金(2011 2010003):中山大学临床医学研究5010计划项目,